Exelixis | EXEL - 资产



金融业
股票价格
USD
资产
USD 2.59B
现金及等价物
USD 226.15M
销售成本
USD 19.95M
流动资产
USD 1.21B
流动负债
USD 370.98M
债务
USD 169.54M
EBIT
USD 251.34M
EBITDA
USD 258.29M
员工
1.15K
EPS每股收益
USD 0.87
股本和储备
USD 1.94B
销售毛利
USD 590.86M
债务利息支出
USD 23.4M
利息收入
USD 16.13M
市值
USD 15.3B
净收入
USD 210.47M
营业费用
USD 359.47M
营业利润
USD 251.34M
普通股股本
USD 253.7M
PE价格收益
13.91
税前利润
USD 267.69M
销售收入
USD 610.8M
销售和管理费用
USD 139.6M
股票
USD 26.61M
贸易债权人
USD 24.15M
应收帐款人
USD 328.95M


资产 更改 日
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Akebia Therapeutics USD 362.52M 14.04M 2026-03
Amgen USD 92.5B 1.92B 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Bayer EUR 107.94B 3.4B 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Cytokinetics USD 1.27B 151.06M 2026-03
Eisai JPY 1.45T 37.11B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Exelixis USD 2.59B 250.83M 2026-03
Genmab DKK 12.87B 5.85B 2025-12
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
MacroGenics USD 217.87M 38.97M 2026-03
Merck USD 128.68B 8.18B 2026-03
Moderna USD 11.49B 850M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 207.62B 542M 2026-03
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sanofi EUR 126.81B 25.48B 2025-12
Takeda JPY 15.45T 44.34B 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Xencor USD 736.85M 138.65M 2026-03